Valuation dashboard for Novavax, Inc. (NVAX) with P/E N/A, P/B -8.07, EV/EBITDA -8.51 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials.
Analysis Summary
Novavax, Inc. reported revenue of $1.12B in the most recent fiscal year, growing at a 5-year CAGR of 118.8%.
Trailing-twelve-month margins: gross margin 77.9%, operating margin -54.9%, net margin -59.9%.
At the current price of $9.35, NVAX has negative trailing earnings (P/E not meaningful) and an ROE of 159.85%. Market capitalisation stands at $1.5B.
Balance sheet quality for NVAX: current ratio of 2.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -8.07 |
| EV / EBITDA | -8.51 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-72.97 |
| vs Current Price | -880.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NVAX | Novavax, Inc. | $1.5B | 159.9% | ||
| TERN | Terns Pharmaceuticals, Inc. | $4.8B | 4.90 | -20.0% | |
| TRVI | Trevi Therapeutics, Inc. | $2.1B | 7.31 | -23.6% | |
| PGEN | Precigen, Inc. | $2.7B | |||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
Price
| Price | $9.35 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 159.85% |
| Return on Invested Capital | -36.14% |
| Return on Assets | -25.92% |
| Gross Margin | 77.85% |
| Operating Margin | -54.94% |
| Net Margin | -59.87% |
Related companies: CVAC · NKTR · NTLA · ORIC · PGEN · TERN · TRVI
Explore sector: Healthcare · Biotechnology
More sections of NVAX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks